Pancreatic Cancer Research

ResearcherNIHR Southampton Biomedical Research CentreActive in the last 2 years

Paul R. Afolabi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0553-1578; OpenAlex author ID A5087878829. Sources: OpenAlex.

Their work

Papers
4 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. Citrulline and Faecal Elastase 1 as a Combined Diagnostic Biomarker for Pancreatic Ductal Adenocarcinoma Last author DOI 10.2139/ssrn.7472539↗
  2. Metabolite Changes Associated with Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers17071150↗
  3. Utilising Pancreatic Exocrine Insufficiency in the Detection of Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers15245756↗
  4. DEPEND study protocol: early detection of patients with pancreatic cancer - a pilot study to evaluate the utility of faecal elastase-1 and 13C-mixed triglyceri… Co-author DOI 10.1136/bmjopen-2021-057271↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Declan McDonnell · 4 shared papers, 2022–2026 · strength 0.95
  2. Zaed Z. R. Hamady · 4 shared papers, 2022–2026 · strength 0.95
  3. Umar H.K. Niazi · 2 shared papers, 2025–2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.